Eli Lilly and Company is acquiring biotech firm AtaiBeckley for an up-front payment of $2.8 billion to integrate the psychedelic drug candidate BPL-003 into its neuroscience portfolio. According to company terms, Lilly will pay $6.75 per outstanding share, with potential milestone payments reaching an additional $1 billion ($2.50 per share), according to the deal terms. … Read more
Genetic Insights into GLP-1R and Mental Health Genetic evidence suggests that lifelong activation of the glucagon-like peptide-1 receptor (GLP-1R) may reduce risks of major depressive disorder (MDD) and bipolar disorder (BD), according to a study published in Translational Psychiatry. Researchers used Mendelian randomization (MR) to analyze data from genome-wide association studies (GWASs), linking genetic variants … Read more
The Hormone-Mood Connection: How the Ghrelin Breakthrough is Redefining Mental Healthcare For decades, the medical community has treated mental health and metabolic health as two separate silos. We treated depression with psychiatry and obesity with nutrition and endocrinology. But a groundbreaking study recently published in Scientific Reports is shattering that wall, suggesting that the link … Read more
The Cognitive Connection: Understanding the Impact of Parental Mental Health parent child mental health support For years, the medical community has focused heavily on treating adults living with severe mental illnesses (SMI). However, a massive shift in perspective is underway, turning the spotlight toward the next generation. Recent large-scale research indicates that the developmental outcomes … Read more